Satellite picture of the United States with beams of light coming out with the Eviti Branded Blue Gradient overlaid

The burden of cancer and autoimmune diseases is heavy on patients, providers, and payers in the United States. Nearly 40 percent of men and women will be diagnosed with cancer at some point during their lifetimes. It’s one of the leading causes of death in our country, and the direct and indirect costs of cancer are staggering. With autoimmune diseases, more than 24 million people are affected, and it is one of the leading causes of disability, morbidity, and mortality.

Navigating increasingly complex therapies in an ever-evolving care landscape while ensuring that quality and costs are aligned to create more positive patient outcomes is exceedingly challenging. That’s why we developed Eviti, a resource that helps payers and providers realize the quickest path to evidence-based, cost-effective, quality care for patients.

We created Eviti from an evolving body of data—including evidence-based standards and therapies—in order to fuel better and more efficient outcomes for patients. Technology can expediently and expertly aid physicians in making the best treatment decisions, eliminating unnecessary and ineffective treatments, and reducing the unjustified costs of care. It also aligns evidence-based care with healthcare plan language and policies to assure payers that their members receive the best possible care, facilitate rapid authorization, and enable appropriate reimbursement. This also assists them in avoiding unnecessary delays in patient care caused by unnecessary appeals, denials, care interruptions, and other inefficiencies.

Why is this decision support needed?

  • Impact: The incidence and prevalence of these diseases is on the rise. Almost 1.9 million new cancer cases are projected in 2021. Many people, too, are affected by autoimmune diseases. With more than 100 known autoimmune diseases, it is the second leading cause of chronic illnesses, particularly in women.

Disease Prevalence graphic showing that there are 1.8 million new cancer cases in 2020, nearly 40% of men and women will be diagnosed with cancer in their lifetimes, and 50 million people suffer from an autoimmune disease

  • Complexity: There is significant complexity in diagnosing and treating cancer and autoimmune diseases. As science gets better and advancements in research and pharmaceuticals are made, identifying effective care plans is also more challenging. New drugs, including more than 1,300 medicines and vaccines for various cancers and more than 300 drugs for autoimmune diseases, are currently in development. While new treatments are promising, it’s often overwhelmingly complex for providers to choose the best course of action for each patient’s unique disease and circumstances. It’s also overwhelming for healthcare plans to review prescribed treatments to approve and authorize payment for care.

Magnitude of new treatment options graphic that says 1300+ new medicines and vaccines in development to treat cancer and 300+ new drugs in development for autoimmune diseases

  • Rising Costs: Improvements in science and technology are often associated with increased costs, but that doesn’t have to be the case. With the right information and technological support, health plans can assist in the delivery of the right information to ensure every patient has the right therapy at the right time and at the right cost.

Cost Burden graphic that says $183 billion will be spent on cancer-related healthcare by 2015 and $246B by 2030 and $100 billion spent annually on treating autoimmune diseases

The burden of cancer and autoimmune disease on our patients, families, providers, payers, and society is over. Everyone needs an informed approach to keep up with these issues to deliver the treatments our patients deserve.

That’s why we do what we do.

Relying on science-backed data, connection, and collaboration, NantHealth remains committed to creating the tools needed to help the fight against cancer and autoimmune diseases.

Check out our complimentary on-demand webinar: “Payer Readiness for Autoimmune Biosimilars“.

Learn More about Eviti

Appropriate, More Affordable Care

Collaborate more effectively with providers to select cancer treatments that maximize solutions and cost-efficiency.

  • Automate Authorization – Streamline the approval process to start care faster, while reducing administrative burden.
  • Collaborate with Confidence – Evidence-based treatments give all stakeholders peace of mind.
  • Optional Preferences – Indicate to providers which proven treatments and clinical trials you prefer.

For clinicians, Eviti Advisor grants access to Eviti’s vast evidence-based treatment library, providing thorough details on the effectiveness, side effects, and cost of potential cancer treatments.

Payers, seeking a clearer view into treatment validity, turn to Eviti Connect. Focused on high-quality, high-value care, the platform offers insight payers need to make reimbursement decisions.

NantHealth’s Eviti Connect is a web-based healthcare payer solution that electronically connects health plans and practices for the authorization of treatment for autoimmune diseases. Eviti Connect:

  • Reduces wasteful payer administrative time and spending by validating appropriate treatment plans at the point of care
  • Reduces denials and appeals
  • Expedites care for the patient

NantHealth | Technology that Simplifies Healthcare.